ESTADOS DE HIPERCOAGULABILIDAD Y OBSTRUCCION DE LA VENA CENTRAL DE LA RETINA





ESTADOS DE HIPERCOAGULABILIDAD Y OBSTRUCCION DE LA VENA CENTRAL DE LA RETINA

(especial para SIIC © Derechos reservados)
La obstrucción de la arteria central de la retina puede producirse por varias condiciones patológicas establecidas. Los estados de hipercoagulabilidad no son habituales, por lo que sólo se justifica su investigación en pacientes con determinadas características.
lahey9.jpg Autor:
Cheung M
Columnista Experto de SIIC
Artículos publicados por Cheung M
Coautor
Marsha C. Cheung M.D.* 
Department of Ophthalmology, University of California at San Francisco, San Francisco, CA*
Recepción del artículo
12 de Febrero, 2004
Primera edición
30 de Julio, 2004
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
La obstrucción de la vena central de la retina (OCVR) es una causa común de pérdida grave de la visión. El examen de todos los pacientes con OVCR incluye evaluación de hipertensión, diabetes, hiperlipidemia, glaucoma y aterosclerosis. Los pacientes sin factores de riesgo habituales a menudo son sometidos a una evaluación extensa para descartar estados de hipercoagulabilidad. Hemos revisado la bibliografía actual respecto de cuáles trombofilias están asociadas con obstrucción de la vena central de la retina. La información presente sugiere que las pruebas de anticuerpos antifosfolípidos e hiperhomocisteinemia se asocian con más recurrencia de OVCR. No se recomiendan las pruebas indiscriminadas de detección de estados hipercoagulables en todos los pacientes con OVCR. Se debe considerar la investigación de estados hipercoagulables en ciertos grupos de pacientes que presentan OVCR, incluyendo a aquellos que son jóvenes y sin factores de riesgo conocidos, los que tienen antecedente familiar de trombosis a edad temprana y los que tienen enfermedad retiniana oclusiva venosa bilateral. La selección cuidadosa de pacientes aumenta la probabilidad de obtener pruebas positivas.

Palabras clave
Estados de hipercoagulabilidad, trombofilia, obstrucción de la vena central de la retina, trombosis venosa, enfermedad retiniana venosa oclusiva


Artículo completo

(castellano)
Extensión:  +/-7.63 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Central retinal vein occlusion (CRVO) is a common cause of severe vision loss. Workup for all patients who present with CRVO includes evaluation for hypertension, diabetes, hyperlipidemia, glaucoma, and atherosclerosis. Those patients without the common risk factors are often subjected to extensive evaluation for hypercoagulable states. We review the current literature regarding which thrombophilias are actually associated with central retinal vein occlusion. Current data suggests that tests for antiphospholipid antibodies and hyperhomocysteinemia are most often associated with CRVO. Widespread screening for hypercoagulable states on all patients with CRVO is not recommended. A hypercoagulable state workup should be considered in certain groups of patients presenting with CRVO including those patients who are young without known risk factors, those with a positive family history for thrombosis at an early age, and/or those with recurrent or bilateral retinal venous occlusive disease. Careful patient selection increases the likelihood for positive tests.

Key words
Hypercoagulable states, thrombophilia, central retinal vein occlusion, venous thrombosis, retinal venous occlusive disease


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Oftalmología
Relacionadas: Hematología, Medicina Interna



Comprar este artículo
Extensión: 7.63 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994;117:429-411.
  2. The Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-282.
  3. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995;102:1434-1444.
  4. Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina 2001;21:408-415.
  5. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001;12:2249-2257.
  6. Lahey JM, Fong DS, Kearney JJ. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers 1999;30:427-434.
  7. McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol 1995;113:456-462.
  8. Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular edema due to central retinal vein occlusion. Br J Ophthalmol 2002;86:247-248.
  9. Quinlan PM, Elman MJ, Bhatt AK, et al. The natural course of central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996;80:203-208.
  10. Gutman FA. Evaluation of a patient with central retinal vein occlusion. Ophthalmology 1983;90:481-483.
  11. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993;37:393-417.
  12. The Eye Disease Case-Control Study Group: Risk factors for CRVO. Arch Ophthalmol 1996;114:545-554.
  13. Martin SC, Butcher A, Martin N, et al. Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol 2002;86:774-776.
  14. Shahsuvaryan ML, Melkonyan AK. Central retinal vein occlusion risk profile: a case control study. Eur J Ophthalmol 2003;13:445-454.
  15. Williamson T. Central retinal vein occlusion: what's the story Br J Ophthalmol 1997;81:698-704.
  16. The Central Vein Occlusion Study Group. Baseline and early natural history report. Arch Ophthalmol 1993;111:1087-1095.
  17. Green WR, Chan CC, Hutchins GM, et al. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 1981;79:371-422.
  18. Colman RW: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, edn 4. Philadelphia: Lippincott Williams & Wilkins: 2001.
  19. Greiner K, Peetz D, Winkgen A, et al. Genetic thrombophilia in patients with retinal vein occlusion. Int Ophthalmol 2001;23:155-160.
  20. Killeen AA. The effect of disease prevalence on the predictive value of diagnostic tests. 1999. Available at: http://www.ipathology.com/Disease%20Prevalence%20Notes.htm.
  21. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002;70:126-132.
  22. Heyreh S, Zimmerman M, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240:180-196.
  23. Lahey JM, Tunc M, Kearney JJ. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years old. Ophthalmology 2002;109:126-131.
  24. Fegan CD. Central retinal vein occlusion and thrombophilia. Eye 2002;16:98-106.
  25. Koster T, Rosendaal FR, deRonde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-1506.
  26. Arruda VR, Annichino-Bizzacchi JM, Costa FF, et al. Factor V Leiden (FVQ 506) is common in Brazilian population. Am J Hematol 1995;49:242-243.
  27. D'Angelo A, Tavola A, Fermo I, et al. Moderate hyperhomocysteinemia and central retinal vein occlusion. Thromb Haemost 2002;87:1078-1079.
  28. Demirci FYK, Guney DB, Akarcay K, et al. The prevalence of factor V Leiden in patients with retinal vein occlusion. Acta Ophthalmol Scand 1999;77:631-633.
  29. Kalayci D, Gurgey A, Guven D, et al. Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. Acta Opthalmol Scand 1999;77:622-624.
  30. Johnson TM, El-Defrawy, Hodge WG, et al. Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion. Retina 2001;21:161-166.
  31. Marcucci R, Bertini L, Giusti B, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001;86:772-776.
  32. Hvarfner C, Hillarp A, Larsson J. Influence of factor V Leiden on the development of neovascularization secondary to central retinal vein occlusion. Br J Ophthalmol 2003;87:305-306.
  33. Zwierzina WD, Kunz F, Miller K. Retinal vascular occlusion in antithrombin III deficiency. Klin Monatsbl Augenheilkd 1985;187:534-536.
  34. Abu el-Asrar AM, al-Momen AK, al Amro S, et al. Prothrombotic states associated with retinal venous occlusion in young adults. Int Ophthalmol 1996-97;20:197-204.
  35. Bertram B, Remky A, Arend O, et al. Protein C, protein S, and antithrombin III in ocular occlusive diseases. Ger J Ophthalmol 1995;4:332-335.
  36. Kruger K, Witt I. Inhibitors of blood coagulation in vascular occlusion of the retina and optic nerve. Fortschr Ophthalmol 1990;87:178-181.
  37. Prince HM, Thurlow PJ, Buchanan RC, et al. Acquired protein S deficiency in a patient with systemic lupus erythematosus causing central retinal vein thrombosis. J Clin Pathol 1995;48:387-389.
  38. Guareschi G, Vigano D'Angelo S, Foresti V, et al. Normal activities of protein C, protein S, and antithrombin III in young patients with retinal vein occlusion. Haematologica 1990;75:483-484.
  39. Pabinger I, Kyrle PA, Heistinger M, et al. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost 1994;71:441-445.
  40. Tekeli O, Gursel E, Buyurgan H. Protein C, protein S, and antithrombin III deficiencies in retinal vein occlusion. Acta Ophthalmol Scand 1999;77:628-630.
  41. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996;80:203-208.
  42. Gleuck CJ, Bell H, Vadlamani L, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999;117:43-49.
  43. Fruschelli M, Puccetti L, Bruni F, et al. Coagulative, fibrinolytic, and metabolic pattern in patients with central retinal vein occlusion. Ophthalmologica 2002;216:108-112.
  44. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human lipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-137.
  45. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein (a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003;14:361-366.
  46. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
  47. Boyd S, Owens D, Gin T, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001;85:1313-1315.
  48. Larsson J, Hillarp A. The prothrombin gene G20210A mutation and the platelet glycoprotein IIIa polymorphism PIA2 in patients with central retinal vein occlusion. Thromb Res 1999;96:323-327.
  49. Salomen O, Moisseiev J, Rosenberg N et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood, Coag Fibrinol 1998;9:617-622.
  50. Incorvaia C, Parmeggiani F, Costagliola C, et al. The heterozygous 20210G/A genotype prevalence in patients affected by central and branch retinal vein occlusion: a pilot study. Graefes Arch Clin Exp Ophthalmol 2001;239:251-256.
  51. Ames PR, Pyke S, Ionnaccone L, et al. Antiphospholipid antibodies, haemostatic variables and thrombosis- a survey of 144 patients. Thromb Haemost 1995;73:768-773.
  52. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685-3691.
  53. Prisco D, Marcucci R, Bertini L, et al. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. Eur J Int Med 2002;13:163-169.
  54. Coniglio M, Platania A, Di Nucci GD, et al. Antiphospholipid protein antibodies are not an uncommon feature in retinal venous occlusions. Thromb Res 1996;83:183-188.
  55. Adamczuk YP, Iglesias Varela ML, Matinuzzo ME, et al. Central retinal vein occlusion and thrombophilia risk factors. Blood Coagul Fibrinolysis 2002;13:623-626.
  56. Cobo-Soriano R, Sanchez-Ramon S, Aparicio MJ et al. Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 1999;128:725-732.
  57. Bashshur ZF, Taher A, Masri AF, et al. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. Retina 2003;23:486-490.
  58. Hartnett ME, Laposat M, Van Cott E. Antiphospholipid antibody syndrome in a six year old female patient. Am J Ophthalmol 2003;135:542-544.
  59. Den Heijer M, Koster T, Blom H, et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996;334:759-762.
  60. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1995;274:1049-1057.
  61. Engbersen AMT, Franken DG, Boers GH, et al. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995;56:142-150.
  62. Kang SS, Wong PW, Zhou JM, et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988;37:611-613.
  63. Zhu BT. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. Histol Histopathol 2002;17:1283-1291.
  64. Santosh-Kumar CR, Deutsch JC, Ryder JW, et al. Unpredictable intraindividual variations in serum homocysteine levels on folic acid supplementation. Eur J Clin Nutr 1997;51:188-192.
  65. Singer DR, Hasan K. Homocysteine and other new risk factors for central retinal vein occlusion: new challenges for the internal medicine physicin. Eur J Int Med 2002;13:160-162.
  66. Pianka P, Almog Y, Man O, et al. Hyperhomocysteinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000;107:1588-1592.
  67. Weger M, Stranger O, Deutschmann H, et al. Hyperhomocysteinemia and MTHFR C677T genotypes in patients with CRVO. Graefs Arch Clin Exp Ophthalmol 2002;240:286-290.
  68. Blondel J, Glacet-Bernard A, Bayani N, et al. Retinal vein occlusion and hyperhomocysteinemia. J Fr Ophthalmol 2003;26:249-253.
  69. Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA, et al. Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol 2002;12:495-500.
  70. Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002;32:308-311.
  71. Brown BA, Marx JL, Ward TP, et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 2002;109:287-290.

Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
Clasificado en
Artículos originales>
Expertos del Mundo

Especialidad principal:
Oftalmología


Relacionadas:
Hematología
Medicina Interna
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618